A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer (2020)


Junttila, Anna; Helminen, Olli; Väyrynen, Juha P.; Ahtiainen, Maarit; Kenessey, Istvan; Jalkanen, Sirpa; Mecklin, Jukka-Pekka; Kellokumpu, Ilmo; Kuopio, Teijo; Böhm, Jan; Mrena, Johanna (2020). Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer. British Journal of Cancer, 123 (11), 1625-1632. DOI: 10.1038/s41416-020-01053-7


JYU-tekijät tai -toimittajat


Julkaisun tiedot

Julkaisun kaikki tekijät tai toimittajat: Junttila, Anna; Helminen, Olli; Väyrynen, Juha P.; Ahtiainen, Maarit; Kenessey, Istvan; Jalkanen, Sirpa; Mecklin, Jukka-Pekka; Kellokumpu, Ilmo; Kuopio, Teijo; Böhm, Jan; et al.

Lehti tai sarja: British Journal of Cancer

ISSN: 0007-0920

eISSN: 1532-1827

Julkaisuvuosi: 2020

Volyymi: 123

Lehden numero: 11

Artikkelin sivunumerot: 1625-1632

Kustantaja: Nature Publishing Group

Julkaisumaa: Britannia

Julkaisun kieli: englanti

DOI: https://doi.org/10.1038/s41416-020-01053-7

Avoin saatavuus: Julkaisukanava ei ole avoin

Julkaisukanavan avoin saatavuus:

Julkaisun avoin saatavuus:


Tiivistelmä

Background: Immune response against cancer has prognostic impact but its role in gastric cancer is poorly known. The aim of the study was to assess the prognostic significance of immune cell score (CD3+, CD8+), tumour immune escape (PD-L1, PD-1) and immune tolerance (Clever-1).

Methods: After exclusion of Epstein-Barr virus positive (n = 4) and microsatellite instable (n = 6) tumours, the study included 122 patients with GC undergoing D2 gastrectomy. CD3+ and CD8+ based ICS, PD-L1, PD-1 and Clever-1 expressions were evaluated. Differences in survival were examined using Cox regression adjusted for confounders. The primary outcome was 5-year survival.

Results: The 5-year overall survival rate was 43.4%. High ICS was associated with improved overall survival (adjusted HR 0.48 (95% CI 0.26-0.87)) compared to low ICS. In the high ICS group, patients with PD-L1 expression (5-year survival 69.2 vs. 53.1%, p = 0.317), high PD-1 (5-year survival 70.6 vs. 55.3% p = 0.312) and high Clever-1 (5-year survival 72.0% vs. 45.5% (p = 0.070) had poor prognosis.

Conclusions: High ICS was associated with improved survival. In the high ICS group, patients with high PD-L1, PD-1 and Clever-1 had poor prognosis highlighting the importance of immune escape and immune tolerance in GC.


YSO-asiasanat: syöpätaudit; mahasyöpä; ennusteet; immuunivaste; fenotyyppi


Liittyvät organisaatiot


OKM-raportointi: Kyllä

Alustava JUFO-taso: 2


Viimeisin päivitys 2020-25-11 klo 07:15